Treatment of chronic bacterial prostatits with amikacin through anal submucosal injection

• 来源期刊: 亚洲男性学杂志(英文版)
• 学科: 医学
• 关键词: 肛门下粘膜 氨基羟丁基卡那霉素 治疗 慢性细菌性前列腺炎
• 年，卷（期）: 2002,（3）
• 页码范围: 163-167
• 页数: 5页
• 分类号: R697.33|R969
• 语种: 中文

摘要

Abstract Aim:To assess the efficacy and safety of anal submucosal injection(ASI)of amikacin in chronic bacterial prostatitis(CBP).Methods:Fifty male outpatients with CBP were randomly diided into two groups.Thirty cases of ASI group were given amikacin 400mg daily by ASI for ten times and the other twenty cases of intramuscular injection(IM)group were given the same drug daily by IM,All patients were evaluated with NIH-Chronic prostatitis symptom index(NIH-CPSI),the bacteria culture of the expressed prostate secretion(EPS),proctoscopic examination,rectal biopsy and the clinical manifestation were checked at pretreatment and on day 7and 90after cessation of therapy,Results:The cure rate ,apparent effective rate and effective rate of ASI group and IM group were 33.3%vs5%(P<0.050,43.3%vs10%(P<0.05)and16.7%vs20%(P>0.05).respectively.The score of NIH-CPSI in both of ASI group and IM group decreased significantly 7days after cessation of therapy,both ASI and IMof amikacin could relieve symptoms within a short time,However,3months after cessation of therapy the score of NIH-CPSIin ASIgroup continued own in spite of no significant differences compared with 7days after cessation of theragy,but the score of IMgroup was rebound nearly colsed to level of pretreatment at23.8±8.5and significantly higher than that of ASI group.The amount of white blood cell(WBC)of EPS in ASIgroup increased slightly at7days after cessation of therapy without significant difference with pretreatment(P>0.050,but it significantly decreased at 3months after cessation of therapy,the amount of WBCof EPS in ASIgroup was lower than that of IM group at 3months after cessation of therapy(P<0.05).Proctoscopic examination of anal canal were normal after ASI therapy and the rectum biopsy showed no obvious histopathologic abnormality at the site of injection except mild focal submucosal infiltration of lymphocytes and plasma cells at 7days after cessation of therapy which disappeared on 3months after cessation of therapy.All patients had no evident complications.Conclusion:ASI could be recommended as a new safe,effective,painless method of antibiotics administration in the treatment of CBP.